N-TERMINAL PROPEPTIDE OF COLLAGEN TYPE III AS A PROPOSED MARKER OF MYOCARDIAL FIBROSIS IN TYPE 2 DIABETES
https://doi.org/10.15829/1728-8800-2018-3-17-21
Abstract
Aim. To evaluate the role of N-terminal procollagen type III propeptide (P3NP) as a proposed marker of myocardial fibrosis in type 2 diabetes (DM2) patients.
Material and methods. In the study, 2 groups of patients participated: with DM2 and non-DM2 (both n=32). All patients underwent clinical and laboratory assessment, including P3NP, electrocardiography, echocardiography. Statistics was done with Mann-Whitney criteria and Spearman correlation.
Results. The level P3NP is significantly higher in DM2 patients (р<0,00001). In DM2 patients, the level of P3NP significantly correlates with increased myocardial mass of the left ventricle (р=0,00026) and myocardial mass index of the left ventricle (р=0,03685).
Conclusion. Echo- and electrocardiographic signs characteristic for myocardial fibrosis (mass increase, voltage decline) in DM2 patients are concomitant with the increase of P3NP. Significant correlation of P3NP and the size of myocardium makes it to propose P3NP as one of possible markers of myocardial fibrosis in DM2 persons.
About the Authors
O. M. Drapkina
I.M. Sechenov First Moscow State Medical University of the Ministry of Health;
National Research Center for Preventive Medicine of the Ministry of Health.
Russian Federation
Moscow
Russian Federation
Moscow
B. B. Gegenava
I.M. Sechenov First Moscow State Medical University of the Ministry of Health. Moscow
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2010; 378: 31-40. DOI: 10.1016/S0140-6736(11)60679-X.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14. DOI:10.1016/j. diabres.2009.10.007.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414, 782-7 (2001). DOI: 10.1038/414782a.
4. Dedov II, Shestakova MV, Vikulova OK. State Register of Diabetes Mellitus in the Russian Federation: Status of 2014 and Prospects for Development. Diabetes mellitus 2015; 3: 5-22. (In Russ.) DOI: 10.14341/DM201535-22.
5. Bauters C, Lamblin N, McFadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003; 2: 1-16. DOI: 10.1186/14752840-2-1.
6. Drapkina OM, Gegenava BB. Fibrosis of the myocardium in patients with diabetes mellitus. Rational pharmacotherapy in cardiology 2013; 9 (1), 62-5. (In Russ
7. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2010; 378: 31-40. DOI: 10.1016/S0140-6736(11)60679-X.
8. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14. DOI:10.1016/j.diabres.2009.10.007.
9. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414, 782-7 (2001). DOI: 10.1038/414782a.
10. Dedov II, Shestakova MV, Vikulova OK. State Register of Diabetes Mellitus in the Russian Federation: Status of 2014 and Prospects for Development. Diabetes mellitus 2015; 3: 5-22. (In Russ.) DOI: 10.14341/DM201535-22.
11. Bauters C, Lamblin N, McFadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003; 2: 1-16. DOI: 10.1186/14752840-2-1.
12. Drapkina OM, Gegenava BB. Fibrosis of the myocardium in patients with diabetes mellitus. Rational pharmacotherapy in cardiology 2013; 9 (1), 62-5. (In Russ.)
Review
For citations:
Drapkina O.M., Gegenava B.B. N-TERMINAL PROPEPTIDE OF COLLAGEN TYPE III AS A PROPOSED MARKER OF MYOCARDIAL FIBROSIS IN TYPE 2 DIABETES. Cardiovascular Therapy and Prevention. 2018;17(3):17-21. (In Russ.) https://doi.org/10.15829/1728-8800-2018-3-17-21
Views:
1040
Email this article 
